

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Servier
Deal Size : $530.0 million
Deal Type : Licensing Agreement
Servier and IDEAYA Biosciences Partner to Bring Darovasertib to Patients Worldwide
Details : The agreement aims to bring IDE 196 (darovasertib), a small molecule developed for patients with uveal melanoma, and a promising treatment for a rare eye cancer, to patients worldwide.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $210.0 million
September 02, 2025
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Servier
Deal Size : $530.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Details : Darovasertib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Uveal Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2025
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Announces Successful FDA Type D Meeting on Phase 3 Design for Darovasertib
Details : IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of primary uveal melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2025
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Gets FDA Breakthrough Status for Darovasertib in Uveal Melanoma
Details : IDE196 (darovasertib) is a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : J.P. Morgan
Deal Size : $143.8 million
Deal Type : Public Offering
Details : The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 27, 2023
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : J.P. Morgan
Deal Size : $143.8 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering
IDEAYA Announces Pricing of Public Offering
Details : The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $125.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed in combination with Crizotinib for metastatic cutaneous m...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2023
Lead Product(s) : Darovasertib,Crizotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed for metastatic uveal melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDE196 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Uveal Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Details : Darovasertib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uveal Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2023
Lead Product(s) : Darovasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
